What’s Hindering BRCA Testing? Cost, Access, and Awareness

The promise of “precision medicine” is that the right patient gets the right drug at the right time. But in the realm of breast cancer, the gateway to that precision—BRCA genetic testing—is currently functioning as a filter of privilege rather than a clinical standard. While guidelines have expanded and the cost of testing has plummeted, … Read more

Palbociclib & HER2+ Breast Cancer: Longer PFS

A significant advancement in the treatment of a particularly aggressive form of breast cancer has been published today in the New England Journal of Medicine. The PATINA study demonstrates that adding palbociclib to standard treatment extends progression-free survival by nearly 15 months in patients with hormone receptor-positive (HR+), HER2-positive metastatic breast cancer – a subtype … Read more